Trial Profile

A Phase Ib Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2020 Results of final efficacy analyses from this trial, including assessment of dose-response, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
14 May 2020 According to a Polyphor media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program which is being held from May 29-31.
04 Jun 2019 Results of 18 and 24 months landmark overall survival data presented at the 55th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com